Q-omics provides the consensus-scored PRDX4 profile across patient tissues and cancer cell-line models. PRDX4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRDX4 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PRDX4 protein abundance shows 39,139 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where PRDX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX4 survival associations across molecular data types. PRDX4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX4 RNA expression–survival associations across cancer types. High PRDX4 expression shows unfavorable associations in KIRP, UVM, KICH, BLCA, MESO and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRDX4 RNA expression.
This table summarizes PRDX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRDX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX4 shows higher tumor expression in KIRC, HNSC, COAD, KIRP, BLCA and LUAD. The KIRC box plot shows higher PRDX4 RNA expression in tumor versus normal tissue (log2 FC = +1.813, t-test p < 0.001).
This table shows molecular features associated with PRDX4 in patient tissues and cancer cell lines. In patient samples, PRDX4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and PANCREAS.
